Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B.

J Med Chem. 2013 Jul 25;56(14):5979-83. doi: 10.1021/jm400487c. Epub 2013 Jul 16.

PMID:
23808545
2.

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT.

Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11.

3.

Biosensor-based small molecule fragment screening with biolayer interferometry.

Wartchow CA, Podlaski F, Li S, Rowan K, Zhang X, Mark D, Huang KS.

J Comput Aided Mol Des. 2011 Jul;25(7):669-76. doi: 10.1007/s10822-011-9439-8. Epub 2011 Jun 10.

PMID:
21660516
4.

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.

Daouti S, Wang H, Li WH, Higgins B, Kolinsky K, Packman K, Specian A Jr, Kong N, Huby N, Wen Y, Xiang Q, Podlaski FJ, He Y, Fotouhi N, Heimbrook D, Niu H.

Cancer Res. 2009 Mar 1;69(5):1924-32. doi: 10.1158/0008-5472.CAN-08-2627. Epub 2009 Feb 24.

5.

A global benchmark study using affinity-based biosensors.

Rich RL, Papalia GA, Flynn PJ, Furneisen J, Quinn J, Klein JS, Katsamba PS, Waddell MB, Scott M, Thompson J, Berlier J, Corry S, Baltzinger M, Zeder-Lutz G, Schoenemann A, Clabbers A, Wieckowski S, Murphy MM, Page P, Ryan TE, Duffner J, Ganguly T, Corbin J, Gautam S, Anderluh G, Bavdek A, Reichmann D, Yadav SP, Hommema E, Pol E, Drake A, Klakamp S, Chapman T, Kernaghan D, Miller K, Schuman J, Lindquist K, Herlihy K, Murphy MB, Bohnsack R, Andrien B, Brandani P, Terwey D, Millican R, Darling RJ, Wang L, Carter Q, Dotzlaf J, Lopez-Sagaseta J, Campbell I, Torreri P, Hoos S, England P, Liu Y, Abdiche Y, Malashock D, Pinkerton A, Wong M, Lafer E, Hinck C, Thompson K, Primo CD, Joyce A, Brooks J, Torta F, Bagge Hagel AB, Krarup J, Pass J, Ferreira M, Shikov S, Mikolajczyk M, Abe Y, Barbato G, Giannetti AM, Krishnamoorthy G, Beusink B, Satpaev D, Tsang T, Fang E, Partridge J, Brohawn S, Horn J, Pritsch O, Obal G, Nilapwar S, Busby B, Gutierrez-Sanchez G, Gupta RD, Canepa S, Witte K, Nikolovska-Coleska Z, Cho YH, D'Agata R, Schlick K, Calvert R, Munoz EM, Hernaiz MJ, Bravman T, Dines M, Yang MH, Puskas A, Boni E, Li J, Wear M, Grinberg A, Baardsnes J, Dolezal O, Gainey M, Anderson H, Peng J, Lewis M, Spies P, Trinh Q, Bibikov S, Raymond J, Yousef M, Chandrasekaran V, Feng Y, Emerick A, Mundodo S, Guimaraes R, McGirr K, Li YJ, Hughes H, Mantz H, Skrabana R, Witmer M, Ballard J, Martin L, Skladal P, Korza G, Laird-Offringa I, Lee CS, Khadir A, Podlaski F, Neuner P, Rothacker J, Rafique A, Dankbar N, Kainz P, Gedig E, Vuyisich M, Boozer C, Ly N, Toews M, Uren A, Kalyuzhniy O, Lewis K, Chomey E, Pak BJ, Myszka DG.

Anal Biochem. 2009 Mar 15;386(2):194-216. doi: 10.1016/j.ab.2008.11.021. Epub 2008 Nov 27.

6.

NMR structure of a complex between MDM2 and a small molecule inhibitor.

Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F.

J Biomol NMR. 2004 Oct;30(2):163-73.

PMID:
15557803
7.

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA.

Science. 2004 Feb 6;303(5659):844-8. Epub 2004 Jan 2.

8.

Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase.

Xu K, Belunis C, Chu W, Weber D, Podlaski F, Huang KS, Reed SI, Vassilev LT.

Biochem J. 2003 May 1;371(Pt 3):957-64.

9.

Site-specific immobilization of antibodies to protein G-derivatized solid supports.

Podlaski FJ, Stern AS.

Methods Mol Biol. 2000;147:41-8. No abstract available.

PMID:
10857083
10.

Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits.

Wang X, Wilkinson VL, Podlaski FJ, Wu C, Stern AS, Presky DH, Magram J.

Eur J Immunol. 1999 Jun;29(6):2007-13.

11.

Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock.

Mattner F, Ozmen L, Podlaski FJ, Wilkinson VL, Presky DH, Gately MK, Alber G.

Infect Immun. 1997 Nov;65(11):4734-7.

12.

Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.

Gately MK, Carvajal DM, Connaughton SE, Gillessen S, Warrier RR, Kolinsky KD, Wilkinson VL, Dwyer CM, Higgins GF Jr, Podlaski FJ, Faherty DA, Familletti PC, Stern AS, Presky DH.

Ann N Y Acad Sci. 1996 Oct 31;795:1-12.

PMID:
8958912
13.

Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE.

Germann T, Guckes S, Bongartz M, Dlugonska H, Schmitt E, Kolbe L, Kölsch E, Podlaski FJ, Gately MK, Rüde E.

Int Immunol. 1995 Oct;7(10):1649-57.

PMID:
8562510
14.

Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice.

Germann T, Szeliga J, Hess H, Störkel S, Podlaski FJ, Gately MK, Schmitt E, Rüde E.

Proc Natl Acad Sci U S A. 1995 May 23;92(11):4823-7.

15.

Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo.

Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kölsch E, Podlaski FJ, Gately MK, Rüde E.

Eur J Immunol. 1995 Mar;25(3):823-9.

PMID:
7705414
16.

Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist.

Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, Gubler U, Presky DH, Stern AS, Gately MK.

Eur J Immunol. 1995 Jan;25(1):200-6.

PMID:
7843232
17.

Interleukin 12 exerts a differential effect on the maturation of neonatal and adult human CD45R0- CD4 T cells.

Shu U, Demeure CE, Byun DG, Podlaski F, Stern AS, Delespesse G.

J Clin Invest. 1994 Oct;94(4):1352-8.

18.

In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-4-producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12.

Wu CY, Demeure CE, Gately M, Podlaski F, Yssel H, Kiniwa M, Delespesse G.

J Immunol. 1994 Feb 1;152(3):1141-53.

PMID:
7905497
19.

IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts.

Chizzonite R, Truitt T, Desai BB, Nunes P, Podlaski FJ, Stern AS, Gately MK.

J Immunol. 1992 May 15;148(10):3117-24.

PMID:
1578138
20.

Molecular characterization of interleukin 12.

Podlaski FJ, Nanduri VB, Hulmes JD, Pan YC, Levin W, Danho W, Chizzonite R, Gately MK, Stern AS.

Arch Biochem Biophys. 1992 Apr;294(1):230-7.

PMID:
1347984
21.

IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts.

Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, Stern AS, Gately MK.

J Immunol. 1991 Sep 1;147(5):1548-56.

PMID:
1715362
22.

Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, et al.

J Immunol. 1991 Aug 1;147(3):874-82.

PMID:
1713608
23.

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, et al.

Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808-12.

24.

Sequence requirements for ligand binding and cell surface expression of the Tac antigen, a human interleukin-2 receptor.

Cullen BR, Podlaski FJ, Peffer NJ, Hosking JB, Greene WC.

J Biol Chem. 1988 Apr 5;263(10):4900-6.

25.

Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction.

Hakimi J, Seals C, Anderson LE, Podlaski FJ, Lin P, Danho W, Jenson JC, Perkins A, Donadio PE, Familletti PC, et al.

J Biol Chem. 1987 Dec 25;262(36):17336-41.

26.

Phylogenetic diversification of immunoglobulin VH genes.

Litman GW, Berger L, Murphy K, Litman R, Podlaski F, Hinds K, Jahn CL, Dingerkus G, Erickson BW.

Dev Comp Immunol. 1984 Summer;8(3):499-514. No abstract available.

PMID:
6500131
27.

Ganglioside profiles of metastases and of metastasizing and nonmetastasizing rat primary mammary carcinomas.

Skipski VP, Carter SP, Terebus-Kekish OI, Podlaski FJ Jr, Peterson RH, Stock CC.

J Natl Cancer Inst. 1981 Dec;67(6):1251-8.

PMID:
6947108

Supplemental Content

Loading ...
Support Center